Innova Captab Limited · NSE:INNOVACAP
Innova Captab — Q3 FY24 Earnings Presentation
31 slides from Innova Captab's earnings presentation, Feb 13, 2024
Slide 1: Intimation of Investor Presentation to Stock Exchanges
INNOVA CAPTAB LIMITED 1281/1, Hilltop Industrial Estate, Near EPIP, Phase-I, Jharmajri, Baddi, Dist. Solan (H.P.)-173205 India. Phone: +91-1795-650820 February 13, 2024 To, To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th Floor Dalal Street, Mum
Slide 2: Q3 & 9M FY24 Investor Presentation
Investor Presentation Q3 & 9M FY24 Investor Presentation
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Innova Captab Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securit
Slide 4: MD’s Commentary
Performance Highlights 03 MD’s Commentary “With the company's listing on stock exchanges, we extend our heartfelt gratitude to all shareholders, employees, and other stakeholders for their immense support & trust. We are delighted to report a healthy performance for the Q3 & 9M FY24 mainly driven by
Slide 5: Q3 & 9M FY24 Performance Highlights
Q3 & 9M FY24 Performance Highlights
Slide 6: Financial Highlights
Performance Highlights 05 Financial Highlights Revenue from Operations EBITDA and EBITDA Margin1 PAT and PAT Margin (In Rs Crs) 15.3% 15.5% 15.5% 8.1% 8.1% 8.3% 302 283 47 25 242 44 23 37 20 Q3 FY23 Q2 FY24* Q3 FY24* Q3 FY23 Q2 FY24* Q3 FY24* Q3 FY23 Q2 FY24* Q3 FY24* Geographic – Wise (%) Business
Slide 7: Financial Highlights
Performance Highlights 06 Financial Highlights Revenue from Operations EBITDA and EBITDA Margin1 PAT and PAT Margin (In Rs Crs) 13.6% 15.1% 7.4% 8.0% 819 685 123 66 93 51 9M FY23 9M FY24* 9M FY23 9M FY24* 9M FY23 9M FY24* Geographic – Wise (%) Business Area (%) 100% 100% Export 9% 100% 100% 21% 9% 1
Slide 8: Quarterly Consolidated Profit & Loss Statement
Performance Highlights 07 Quarterly Consolidated Profit & Loss Statement Profit and Loss (Rs. Crs) Q3 FY24# Q3 FY23 YoY Q2 FY24# QoQ Revenue from Operations 302.5 242.0 25.0% 282.9 6.9% Other Income 2.3 2.7 3.3 Total Income 304.8 244.7 24.6% 286.3 6.5% Cost of Material Consumed 202.1 176.8 191.5 Emp
Slide 9: Nine Months Consolidated Profit & Loss Statement
Performance Highlights 08 Nine Months Consolidated Profit & Loss Statement Profit and Loss (Rs. Crs) 9M FY24# 9M FY23 YoY FY23 Revenue from Operations 818.7 685.4 19.4% 926.4 Other Income 6.8 6.6 9.2 Total Income 825.5 692.0 19.3% 935.6 Cost of Material Consumed 560.1 511.6 691.6 Employee Cost 64.8
Slide 10: Corporate Snapshot
Corporate Snapshot
Slide 11: Innova Captab – At a Glance
Corporate Snapshot 10 Innova Captab – At a Glance Integrated Pharmaceutical Company in India with Presence Across the Pharmaceutical Value Chain 1 Contract Development and Manufacturing 4 Manufacturing Units 180+ 2 Baddi | 1 Dehradun | 1 Taloja CDMO Customers Business 2 Domestic Branded Generics Seg
Slide 12: The Evolution
Corporate Snapshot 11 The Evolution Major Events and Milestones 1993 2006 1995 2010 2003 20132005 ▪ Established first manufacturing ▪ Commenced operations at a new ▪ Received GMP Certificate for cephalosporin plant in Baddi, Himachal Pradesh dedicated Cephalosporin block (“C products from the Minist
Slide 13: Key Strengths
Key Strengths
Slide 14: Key Strengths
13 Key Strengths Diversified Product Portfolio 01 04 R&D Centric Organization Deep Engagement with 02 Clients 05 Experienced Promoters and Management Team State of the Art Manufacturing Capabilities 03 06 Consistent Financial Performance
Slide 15: 1. Diversified Product Portfolio
Key Strengths 14 1. Diversified Product Portfolio Presence Across the Pharmaceuticals Value Chain Including Manufacturing, Distribution, Marketing and Exports CDMO Services and Products Domestic Branded Generics Sharon Bio Medicine Ltd • Comprehensive CDMO Formulation capabilities offering • Consist
Slide 16: 2. Deep Engagement with Clients
Key Strengths 15 2. Deep Engagement with Clients Developed Strong Relationships across the Indian Pharmaceutical Industry Revenue from CDMO Revenue from CDMO Revenue from CDMO Number of CDMO Revenue from CDMO1 Customers > 10 years customers with customers < 5 Customers1 relationship1 5-10 years1 yea
Slide 17: 3. State of the Art Manufacturing Capabilities
Key Strengths 16 3. State of the Art Manufacturing Capabilities Our Manufacturing Capacity Helps Us to Provide Customers with Large Volumes and Satisfy their Requirements Second highest Fixed Asset Turnover ratio Ranked third among CDMO players in terms of tablet and and ROCE among the CDMO formulat
Slide 18: 3. Long Runway of Growth
Key Strengths 17 3. Long Runway of Growth Baddi Plant Dehradun | Taloja Plant Greenfield project at Jammu Capacity 45% - 50% Utilization 48% -50% FY23 revenue Un-utilized Optimum FY23 Acquired FY25- to Rampup- 2-4 Optimum FY23 revenue Un-utilized Optimum Utilization years Rs 936 crs Utilization in R
Slide 19: 4. R&D Centric Organization
Key Strengths 18 4. R&D Centric Organization R&D is Critical to Maintaining Our Competitive Position and Addressing Changing Consumer and Industry Trends Dedicated R&D laboratory and pilot equipment located at Baddi, Himachal Pradesh which is 1 recognized by the DSIR for in-house R&D work Equipped w
Slide 20: 5. Experienced Promoters and Management Team
Key Strengths 19 5. Experienced Promoters and Management Team Qualified and Experienced Management Team Manoj Kumar Lohariwala Vinay Kumar Lohariwala Jayant Vasudeo Rao Archit Aggarwal Chairman & Whole-time Director Managing Director Whole-time Director Non-Executive Director • Bachelor’s in Commerc
Slide 21: 6. Consistent Financial Performance
Key Strengths 20 6. Consistent Financial Performance Strong Financial Performance with Visible Growth Profile Revenue from operations EBITDA and EBITDA Margin PAT and PAT Margin 13.6% 12.4% 13.3% 8.4% 8.0% 7.3% 926 801 123 68 64 99 411 35 56 FY21 FY22 FY23 FY21 FY22 FY23 FY21 FY22 FY23 ROE / ROCE Fi
Slide 22: Growth Strategies
Growth Strategies
Slide 23: Key Growth Strategies
Growth Strategies 22 Key Growth Strategies ▪ Establishing Cephalosporin, Penicillin, Penum & BFS blocks to manufacture Tablets, Capsules, Dry Powder Injection, Dry Syrup & BFS at new Greenfield Expansion at Jammu greenfield site in Jammu. Anticipate benefitting from the New Central Sector Scheme for
Slide 24: Historical Financial Highlights
Historical Financial Highlights
Slide 25: Consolidated Profit & Loss Statement
Historical Financial Highlights 24 Consolidated Profit & Loss Statement Profit and Loss (Rs. Crs) FY23 FY22 FY21 Revenue from Operations 926.4 800.5 410.7 Other Income 9.2 2.9 1.4 Total Revenue 935.6 803.4 412.0 Cost of Materials Consumed 691.6 617.9 310.7 Employee Cost 54.8 40.5 22.3 Other Expenses
Slide 26: Consolidated Balance Sheet
Historical Financial Highlights 25 Consolidated Balance Sheet Assets (Rs. Crs) FY23 FY22 FY21 Equity & Liabilities (Rs. Crs) FY23 FY22 FY21 Non - Current Assets 261.9 196.4 99.1 Total Equity 276.5 208.6 144.8 Property, plant and equipment 150.1 156.6 76.4 Share Capital 48.0 12.0 12.0 Right of use as
Slide 27: Cash Flow Statement
Historical Financial Highlights 26 Cash Flow Statement Particulars (Rs. Crs) FY23 FY22 FY21 Net Profit Before Tax 91.8 85.7 46.3 Adjustments for: Non -Cash Items / Other Investment or Financial Items -25.9 -15.3 9.6 Operating profit before working capital changes 117.7 101.0 55.9 Changes in working
Slide 28: Listed on BSE & NSE on 29th December 2023
Delivering value to Stakeholders 27 Listed on BSE & NSE on 29th December 2023 ▪ Company raised Rs 570 crs via Fresh Issue of shares for Rs 320 crs and Offer for Sale of Rs 250 crs ▪ IPO subscribed 55.26 times with public issue subscribed 17.15 times in the retail category, 116.73 times in the QIB ca
Slide 29: Utilization of IPO Proceeds
28 Utilization of IPO Proceeds Particulars (Rs. Crs) Original Cost Utilization in FY24 Amount Un-utilized* Repayment and/or prepayment in part or in full, of certain outstanding loans of 144.4 144.4 - the Company Investment in the Subsidiary, UML, for repayment and / or prepayment in part or 23.6 23
Slide 30: Abbreviations
29 Abbreviations Earnings Before Interest, Taxes, Depreciation and ANDA Abbreviated New Drug Application EBITDA Amortization API Active Pharmaceutical Ingredient FY Financial Year / Fiscal Year B2B Business to Business HPLC High Pressure Liquid Chromatography CAGR Compound Annual Growth Rate IBC Ins
Slide 31: Thank You!
Thank You! Innova Captab Limited : Investor Relations Advisor : Strategic Growth Advisors Pvt. Ltd. Innova Captab Ltd. CIN - U74140MH2010PTC204285 CIN – U24246MH2005PLC150371 Ms. Shaily Patwa / Mr. Shrikant Sangani Mr. Lokesh Bhasin Email – shaily.p@sgapl.net / shrikant.sangani@sgapl.net Email – inv